Promising new study for Her2+ bc

MTwoman

New study out of University of Munich for early Her2+ bc:

http://ascopubs.org/doi/pdf/10.1200/JCO.2016.71.9815

(full pdf link)

Lumpie

"Conclusion

The ADAPT HER2-positive/HR-positive trial demonstrates that neoadjuvant T-DM1 (with or without ET) given for only 12 weeks results in a clinically meaningful pCR rate. Thus, a substantial number of patients are spared the adverse effects of systemic chemotherapy."

very exciting news! Chemotherapy is nasty stuff, losing one's hair is SO demoralizing, and when you look a the statistics on recurrence rates, it seems kind of marginal to me how much good it does. Very encouraging that clinical trails on HER2-positive patients look promising! Thanks for sharing this study, MTwoman!